Related Experiment Video

Updated: Mar 15, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Sorafenib plus cisplatin for hepatocellular carcinoma

Vicki Brower

    The Lancet. Oncology
    |September 13, 2016
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    1.4K
    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
    09:49

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

    Published on: December 2, 2013

    10.9K

    Related Experiment Videos

    Last Updated: Mar 15, 2026

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
    06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    9.6K
    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    1.4K
    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
    09:49

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

    Published on: December 2, 2013

    10.9K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    3.9K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K

    Articles linked to this work by shared authors, journal, and citation graph.

    Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

    The Lancet. Oncology·2026

    Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

    The Lancet. Oncology·2026

    Advancing oncology education in low-income and middle-income African settings: global insights for local action.

    The Lancet. Oncology·2026

    Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

    The Lancet. Oncology·2026

    Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

    The Lancet. Oncology·2026

    Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

    The Lancet. Oncology·2026

    Analysis of real-world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma.

    Cancer·2026

    RETRACTION: USP44 Suppresses Proliferation and Enhances Apoptosis in Colorectal Cancer Cells by Inactivating the Wnt/β-catenin Pathway via Axin1 Deubiquitination.

    Cell biology international·2026

    First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data.

    Expert review of pharmacoeconomics & outcomes research·2026

    Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis.

    International journal of urology : official journal of the Japanese Urological Association·2026

    Patterns of radiological response to procarbazine and CCNU polychemotherapy in patients with oligodendroglioma.

    Neuro-oncology advances·2026

    Durable Complete Response Following Nivolumab Discontinuation in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma Complicated by Bullous Pemphigoid: A Case Report.

    Cureus·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us